Michelle A Neben1, William G Morice, Ayalew Tefferi. 1. Division of Hematology and Internal Medicine; Division of Hematopathology, Mayo Clinic, Mayo Medical School, Rochester, MN 55905, USA.
Abstract
OBJECTIVE: Standard clinical and laboratory evaluations and novel laboratory techniques were used to identify patients with T-cell large granular lymphocyte leukemia (LGLL) and those with natural killer-cell variants of LGLL for comprehensive clinical evaluation. METHODS: We used bone marrow histologic analysis, immunophenotypic markers of clonality, and T-cell-receptor gene rearrangement studies to identify patients. RESULTS: The study identified 44 patients with T-cell LGLL and 14 with natural killer-cell LGLL. The two disorders were similar in sex and age distribution of patients; peripheral blood lymphocyte, neutrophil, and platelet counts; and incidence of rheumatoid arthritis. Among the two groups, patients with the T-cell LGLL presented with significantly lower hemoglobin concentrations (P < 0.04) and a higher frequency of palpable splenomegaly (P < 0.01). CONCLUSION: Overall disease progression and response to immunosuppressive therapy are similar between T-cell and natural killer-cell variants of LGLL.
OBJECTIVE: Standard clinical and laboratory evaluations and novel laboratory techniques were used to identify patients with T-cell large granular lymphocyte leukemia (LGLL) and those with natural killer-cell variants of LGLL for comprehensive clinical evaluation. METHODS: We used bone marrow histologic analysis, immunophenotypic markers of clonality, and T-cell-receptor gene rearrangement studies to identify patients. RESULTS: The study identified 44 patients with T-cell LGLL and 14 with natural killer-cell LGLL. The two disorders were similar in sex and age distribution of patients; peripheral blood lymphocyte, neutrophil, and platelet counts; and incidence of rheumatoid arthritis. Among the two groups, patients with the T-cell LGLL presented with significantly lower hemoglobin concentrations (P < 0.04) and a higher frequency of palpable splenomegaly (P < 0.01). CONCLUSION: Overall disease progression and response to immunosuppressive therapy are similar between T-cell and natural killer-cell variants of LGLL.
Authors: E Poullot; R Zambello; F Leblanc; B Bareau; E De March; M Roussel; M L Boulland; R Houot; A Renault; T Fest; G Semenzato; T Loughran; T Lamy Journal: Ann Oncol Date: 2014-08-05 Impact factor: 32.976
Authors: T P Loughran; L Zickl; T L Olson; V Wang; D Zhang; H L M Rajala; Z Hasanali; J M Bennett; H M Lazarus; M R Litzow; A M Evens; S Mustjoki; M S Tallman Journal: Leukemia Date: 2014-09-13 Impact factor: 11.528
Authors: Natali Pflug; Annika Littauer; David Beverungen; Aleksandra Sretenovic; Linus Wahnschaffe; Till Braun; Annika Dechow; Dennis Jungherz; Moritz Otte; Astrid Monecke; Enrica Bach; Georg-Nikolaus Franke; Sebastian Schwind; Madlen Jentzsch; Uwe Platzbecker; Marco Herling; Vladan Vucinic Journal: Front Oncol Date: 2022-01-05 Impact factor: 6.244